Delcath Systems, Inc. (DCTH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Delcath Systems, Inc. (DCTH) Healthcare & Pipeline Overview

Delcath Systems, Inc. is an interventional oncology company specializing in treatments for primary and metastatic liver cancers in the United States and Europe. Its flagship product, HEPZATO KIT, is a melphalan for injection/hepatic delivery system designed to administer high-dose chemotherapy directly to the liver while managing systemic exposure and associated side effects.

What Is the Investment Thesis for DCTH?

Delcath Systems, Inc. presents an investment profile centered on its specialized interventional oncology platform, primarily the HEPZATO KIT/CHEMOSAT system, targeting primary and metastatic liver cancers. The company's value proposition is underpinned by its unique hepatic delivery system, which aims to improve patient outcomes by delivering high-dose chemotherapy directly to the liver while minimizing systemic toxicity. With a robust gross margin of 86.0%, the company demonstrates strong product economics, suggesting significant profitability potential as sales volumes increase. Key growth catalysts include the successful completion and regulatory approval of the FOCUS clinical trial for metastatic hepatic dominant Uveal Melanoma in the United States, which would unlock a new, substantial market. Further expansion of CHEMOSAT adoption across European medical centers and the potential for new indications beyond uveal melanoma represent additional drivers. However, the company currently reports a low profit margin of 0.6% and a high P/E ratio of 808.39, reflecting its early commercialization stage and significant reliance on future clinical and commercial success. Potential risks include regulatory hurdles, clinical trial outcomes, market penetration challenges, and intense competition within the oncology space. The company's beta of 0.54 suggests lower volatility relative to the broader market.

Based on FMP financials and quantitative analysis

DCTH Key Highlights

Market capitalization stands at $548M, reflecting its valuation within the specialized medical devices sector.

• Achieved a high gross margin of 86.0%, indicating strong product-level profitability for its hepatic delivery system.
• Reports a profit margin of 0.6%, suggesting the company is in an early commercialization phase with significant operational investments.
• Trades at a P/E ratio of 808.39, indicating high market expectations for future earnings growth and profitability.
• Operates with a Beta of 0.54, suggesting lower volatility compared to the overall market, potentially appealing to risk-averse investors.

Who Are DCTH's Competitors?

DCTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DCTH's Key Strengths?

Proprietary HEPZATO KIT/CHEMOSAT system offers a unique regional chemotherapy delivery method.

• High gross margin of 86.0% indicates strong product economics once commercial scale is achieved.
• Established commercial presence and regulatory clearance for CHEMOSAT in European markets.
• Focused clinical development program (FOCUS trial) targeting an unmet need in metastatic uveal melanoma.

What Are DCTH's Weaknesses?

Very low profit margin of 0.6% suggests significant operating expenses relative to current revenue.

• High P/E ratio of 808.39 indicates market expectations for substantial future growth and profitability not yet realized.
• Significant reliance on the successful outcome and regulatory approval of a single lead product (HEPZATO KIT) in the US.
• Limited product diversification, making the company vulnerable to setbacks with its core technology.

What Could Drive DCTH Stock Higher?

DCTH catalyst: Potential US regulatory approval for the HEPZATO KIT for metastatic hepatic dominant Uveal Melanoma, expected to open a significant new market.

• Announcement of positive top-line data or successful completion of the ongoing FOCUS clinical trial, validating the efficacy and safety profile of HEPZATO.
• Continued expansion of commercial adoption and utilization of the CHEMOSAT Hepatic Delivery System across existing and new European markets.
• Initiation of clinical studies for new indications, potentially expanding the addressable market for the HEPZATO platform beyond uveal melanoma.

What Are the Key Risks for DCTH?

Rich valuation — a P/E of 808.39 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Clinical trial risk, specifically the potential for unfavorable outcomes or delays in the ongoing FOCUS trial, which could impact US regulatory approval.
• Regulatory hurdles, including the possibility of delays, additional data requests, or outright rejection of the HEPZATO KIT by the FDA in the United States.
• Market adoption and reimbursement challenges for a specialized, high-cost therapy, potentially limiting commercial uptake even with regulatory approval.
• Intense competition from other established and emerging treatments for liver cancers, including systemic therapies, surgical interventions, and other device-based approaches.
• Financial performance risks, including the challenge of converting a high gross margin into sustainable profitability given current operating expenses and market development costs.

What Are the Growth Opportunities for DCTH?

• Expansion of HEPZATO KIT in the US Market: The primary growth driver for Delcath Systems, Inc. is the anticipated regulatory approval and subsequent commercial launch of the HEPZATO KIT in the United States for metastatic hepatic dominant Uveal Melanoma. Successful completion of the ongoing FOCUS clinical trial and favorable review by the FDA would open access to a significant market segment with unmet medical needs. The market for uveal melanoma, while rare, represents a critical area, especially for patients with liver metastases where treatment options are limited. This expansion would leverage the company's existing clinical data and establish a new revenue stream, potentially within the next 1-3 years, contingent on regulatory timelines and market adoption.
• Increased Adoption and Geographic Expansion of CHEMOSAT in Europe: Delcath already commercializes its hepatic delivery system as CHEMOSAT in Europe, where it is used for a range of liver cancers. A key growth opportunity lies in deepening market penetration within existing European countries and expanding into new territories where regulatory approvals are feasible. This involves educating medical professionals on the benefits of regional chemotherapy and securing favorable reimbursement policies. The European market for liver cancer treatments is substantial, and increased utilization of CHEMOSAT could drive consistent revenue growth over the next 3-5 years as more medical centers adopt the specialized device for their interventional oncology programs.
• Development of New Indications for the HEPZATO Platform: While currently focused on metastatic uveal melanoma, the HEPZATO platform's core technology—localized chemotherapy delivery to the liver—has potential applicability across a broader spectrum of primary and metastatic liver cancers, such as hepatocellular carcinoma (HCC) or colorectal cancer liver metastases. Pursuing additional clinical trials for these indications could dramatically expand Delcath's total addressable market. Each new indication would represent a distinct market opportunity, potentially unlocking multi-billion dollar segments within the oncology space over a 5-10 year horizon, contingent on successful clinical development and regulatory pathways.
• Positive Outcomes from the FOCUS Clinical Trial: The ongoing FOCUS clinical trial for metastatic hepatic dominant Uveal Melanoma is a critical near-term catalyst. Positive results demonstrating significant objective response rates or improved patient outcomes could not only lead to US regulatory approval but also enhance physician confidence and accelerate adoption globally. Strong clinical data provides a robust foundation for market differentiation and competitive advantage, supporting premium pricing and broader acceptance among oncology specialists. Such an outcome, expected within the next 1-2 years, would validate the HEPZATO platform and potentially de-risk future development efforts.
• Strategic Partnerships and Collaborations: Delcath could pursue strategic partnerships with larger pharmaceutical or medical device companies to accelerate market penetration, particularly in regions where it lacks a direct commercial footprint. Such collaborations could involve co-promotion agreements, licensing arrangements, or even joint development efforts for new applications of the hepatic delivery system. These partnerships could provide access to greater financial resources, broader distribution networks, and complementary technologies, thereby enhancing Delcath's market reach and product pipeline efficiency over the next 3-7 years, while potentially mitigating commercialization risks.

What Are DCTH's Competitive Advantages?

• Proprietary hepatic delivery system (HEPZATO KIT/CHEMOSAT) for targeted chemotherapy, offering a unique regional treatment approach.
• Established regulatory clearances in Europe (CE Mark) for the CHEMOSAT system, facilitating commercialization in key markets.
• Clinical data generated from trials like the FOCUS study, providing evidence of efficacy and safety in specific liver cancer indications.
• Specialized focus within the niche field of interventional oncology for liver-dominant malignancies, creating a barrier to entry for general oncology companies.

What Does DCTH Do?

Delcath Systems, Inc., established in 1988 and headquartered in New York, New York, is an interventional oncology company dedicated to addressing the critical need for advanced treatments for primary and metastatic liver cancers across the United States and Europe. The company's core innovation lies in its proprietary drug-device combination product, the HEPZATO KIT. This system comprises melphalan for injection and a specialized hepatic delivery system, meticulously engineered to administer high-dose chemotherapy directly to the liver. A key differentiator of the HEPZATO KIT is its ability to achieve targeted therapeutic concentrations within the liver while simultaneously controlling systemic exposure, thereby mitigating the severe side effects typically associated with conventional systemic chemotherapy. This targeted approach represents a significant advancement in regional chemotherapy delivery, aiming to maximize efficacy while minimizing systemic toxicity for patients with challenging liver-dominant malignancies. Delcath's clinical development efforts are prominently showcased through its FOCUS clinical trial. This pivotal study is designed to investigate the objective response rate of HEPZATO in patients diagnosed with metastatic hepatic dominant Uveal Melanoma, a rare and aggressive form of cancer with limited treatment options. The successful progression and outcomes of this trial are critical for potential regulatory approval and broader market access in the United States. Beyond its investigational status in the U.S., Delcath has already established a commercial presence in Europe. Here, the HEPZATO system is available as a stand-alone medical device under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or simply CHEMOSAT. This European offering allows medical centers to treat a diverse range of liver cancers, leveraging the system's ability to deliver regional chemotherapy effectively. The company's strategy involves continuing to expand the adoption of CHEMOSAT across European markets, building on its established regulatory clearances. With a workforce of 96 employees, Delcath Systems, Inc. continues to focus on advancing its interventional oncology platform, aiming to provide innovative solutions for patients facing complex liver cancer diagnoses and improve their treatment outcomes through localized, high-impact therapy. The company's strategic focus on both clinical development and commercialization in key global markets underscores its commitment to becoming a significant player in the specialized field of liver cancer treatment, addressing unmet medical needs with its unique drug-device platform.

What Products and Services Does DCTH Offer?

• Develops and commercializes specialized treatments for primary and metastatic liver cancers.
• Offers the HEPZATO KIT, a drug-device combination for targeted chemotherapy delivery.
• Administers high-dose melphalan directly to the liver using a hepatic delivery system.
• Aims to control systemic exposure to chemotherapy, reducing systemic side effects.
• Conducts the FOCUS clinical trial for metastatic hepatic dominant Uveal Melanoma in the US.
• Provides the CHEMOSAT Hepatic Delivery System in Europe for various liver cancers.
• Focuses on interventional oncology, a sub-specialty combining imaging and minimally invasive procedures.

How Does DCTH Make Money?

• Generates revenue from the sale of the CHEMOSAT Hepatic Delivery System to medical centers in Europe.
• Anticipates revenue from the sale of the HEPZATO KIT (melphalan for injection/hepatic delivery system) in the United States upon regulatory approval.
• Potentially explores licensing agreements or strategic partnerships for broader market access or technology development.

What Industry Does DCTH Operate In?

Delcath Systems, Inc. operates within the highly specialized and evolving interventional oncology segment of the Medical Devices industry. This sector is characterized by a growing emphasis on targeted, minimally invasive therapies designed to deliver potent treatments directly to tumor sites, thereby enhancing efficacy and reducing systemic side effects. The global market for liver cancer treatments is substantial, driven by increasing incidence rates of both primary liver cancer (hepatocellular carcinoma) and metastatic liver disease, particularly from colorectal and uveal melanomas. Delcath's HEPZATO KIT/CHEMOSAT system positions the company as a provider of a unique regional chemotherapy delivery solution, differentiating it from traditional systemic chemotherapy, radiation, and surgical approaches. The competitive landscape includes established pharmaceutical companies with systemic oncology drugs, other device manufacturers offering ablation or embolization technologies, and emerging biotechs developing novel targeted therapies. Delcath's strategy is to carve out a niche by offering a specialized drug-device combination that provides a distinct therapeutic option for liver-dominant cancers, particularly in cases where systemic treatments have limited efficacy or are poorly tolerated. The company's focus on metastatic hepatic dominant Uveal Melanoma highlights its pursuit of unmet needs within this complex therapeutic area.

Who Are DCTH's Key Customers?

• Interventional oncologists, surgical oncologists, and medical oncologists specializing in liver cancer.
• Hospitals, academic medical centers, and specialized cancer treatment clinics in Europe and, potentially, the United States.
• Patients diagnosed with primary or metastatic liver cancers, particularly those with liver-dominant disease.

Delcath Systems, Inc. Financial Trajectory

Delcath Systems, Inc. (DCTH) reported $29.1M in revenue for Q2 FY2026, reflecting 16.6% growth compared to the prior quarter. The company recorded net income of $2.7M, with diluted EPS of $0.07. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, DCTH averaged $0.00 in diluted EPS.

Company Profile

Delcath Systems, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Queensbury, US. The company is led by CEO Gerard J. Michel. DCTH has traded publicly since 2018.

How Delcath Systems, Inc. Is Valued

Delcath Systems, Inc. carries a market capitalization of $548M, placing it in the small-cap category. Analyst price targets span from $17.00 to $32.00, with a consensus of $24.50. At the current price of $15.88, that implies approximately 54% upside potential. Relative to its peer group, DCTH's quantitative score of 92/100 is above the peer average of 63/100.

Return on equity for Delcath Systems, Inc. stands at 0.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.4%, showing how much profit it generates from its asset base. DCTH trades at a trailing price-to-earnings ratio of 808.39, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.1%, the inverse of the P/E and a quick read on earnings relative to price.

Delcath Systems, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 17.22 places it in the safe zone, indicating low near-term bankruptcy risk.

Delcath Systems, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 74.2% above estimates on average.

Over the past six months, Delcath Systems, Inc. insiders filed 5 SEC Form 4 transactions — 0 sales and 5 purchases. On net that is roughly 113K shares acquired (about $1.3M) — insiders putting money in tends to read as conviction.

DCTH Financials

DCTH Latest News

DCTH Analyst Consensus

DCTH MoonshotScore

What Investors Ask About Delcath Systems, Inc. (DCTH) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources